Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 6
Submit an article Journal homepage
953
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Hepatitis C: how has France limited the expenses related to new treatments?

Anne-Laure MouterdeEvaluation and Proper Use of Health Products, General Agency of Equipment and Health Products, Assistance Publique-Hôpitaux de Paris (AP-HP) 7 rue du Fer à Moulin, 75005Paris, FranceCorrespondence[email protected]
View further author information
,
François BocquetEvaluation and Proper Use of Health Products, General Agency of Equipment and Health Products, Assistance Publique-Hôpitaux de Paris (AP-HP) 7 rue du Fer à Moulin, 75005Paris, France;Health Law and Health Economics Departement, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, 4 avenue de l'Obervatoire, 75006Paris, France;Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité. 45 rue des Saints-Pères, 75006Paris, FranceView further author information
,
Isabelle FusierEvaluation and Proper Use of Health Products, General Agency of Equipment and Health Products, Assistance Publique-Hôpitaux de Paris (AP-HP) 7 rue du Fer à Moulin, 75005Paris, FranceView further author information
&
Pascal PaubelEvaluation and Proper Use of Health Products, General Agency of Equipment and Health Products, Assistance Publique-Hôpitaux de Paris (AP-HP) 7 rue du Fer à Moulin, 75005Paris, France;Health Law and Health Economics Departement, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, 4 avenue de l'Obervatoire, 75006Paris, France;Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité. 45 rue des Saints-Pères, 75006Paris, FranceView further author information
Pages 655-657 | Received 16 Aug 2016, Published online: 27 Oct 2016
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgment

The authors would like to thank all the AP-HP’s members of the hepatitis C group of experts.

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This manuscript has no funding.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib.
Source: BMC

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.